Harbour BioMed Strengthens Alliance with Spruce Biosciences
In a noteworthy development, Harbour BioMed, a prominent global biopharmaceutical company focused on innovative antibody therapies, has made a significant move by acquiring common stock in Spruce Biosciences, Inc. This acquisition reflects their deepening collaboration and shared vision in advancing medical treatments.
Details of the Acquisition
Through its wholly-owned subsidiary, Harbour BioMed exercised its warrant to obtain common stock in Spruce Biosciences. With this transaction, Harbour now holds around 3.8% of the total outstanding shares and approximately 3.1% of the fully diluted shares in Spruce. This strategic investment emphasizes the commitment of Harbour BioMed to enhance its partnership with Spruce Biosciences.
About the Collaboration
The warrant acquired by Harbour BioMed's subsidiary was initially issued to them and other minority stakeholders as part of a licensing and collaboration agreement with Spruce. This partnership aims to propel the development of SPR202, a highly targeted monoclonal antibody designed to treat numerous conditions, including congenital adrenal hyperplasia. The agreement signifies the transition from a basic licensor-licensee bond to a well-aligned strategic collaboration.
Leadership Insights
Dr. Jingsong Wang, who serves as the Founder, Chairman, and CEO of Harbour BioMed, expressed enthusiasm regarding this pivotal moment in the company's journey. He remarked, "This warrant exercise represents a significant milestone in our relationship with Spruce Biosciences. It marks a shift to a truly collaborative partnership, enhancing our combined efforts to expedite the development of transformative therapies for patients globally."
About Harbour BioMed
Harbour BioMed is at the forefront of biopharmaceutical innovation, dedicated to revealing and bringing to market groundbreaking antibody therapeutics in the fields of immunology and oncology. The company is recognized for cultivating a robust and unique pipeline, driven by internal research and development, as well as strategic global partnerships and selective acquisitions within the industry.
The proprietary technology platform, known as Harbour Mice, allows for the generation of fully human monoclonal antibodies utilizing both traditional and innovative formats. Their advancements, including HCAb-based immune cell engagers and immune cell antagonists, enable them to create biologics that tackle diseases in ways traditional therapies cannot. By leveraging the Harbour Mice platform together with cutting-edge technologies, they are establishing an efficient method for discovering next-generation therapeutic antibodies.
Future Prospects
The relationship between Harbour BioMed and Spruce Biosciences is anticipated to generate promising developments in the creation of new therapies. This strategic investment highlights the dynamic landscape of biopharmaceutical collaborations aimed at improving patient outcomes. Experts believe that their combined expertise and technologies could lead to remarkable advancements in their respective fields.
Frequently Asked Questions
What strategic move did Harbour BioMed make with Spruce Biosciences?
Harbour BioMed acquired common stock in Spruce Biosciences, enhancing their strategic partnership.
What percentage of Spruce's shares does Harbour BioMed own?
After the acquisition, Harbour BioMed holds approximately 3.8% of Spruce's total outstanding shares.
What is the purpose of the collaboration between Harbour BioMed and Spruce?
The collaboration aims to advance the development of SPR202, a specific monoclonal antibody for various disorders.
Who is the CEO of Harbour BioMed?
Dr. Jingsong Wang is the Founder, Chairman, and CEO of Harbour BioMed.
What technologies does Harbour BioMed utilize in their research?
They use the Harbour Mice platform for generating monoclonal antibodies and have developed unique technologies for creating innovative biologics.
